Study of third-generation EGFR-TKI pills after surgery for early-stage lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well a type of targeted therapy pill (called a third-generation EGFR-TKI) works when taken after surgery for early-stage non-small cell lung cancer that has certain high-risk features and an EGFR mutation. It aims to see if this treatment can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with stage IA non-small cell lung cancer that has high-risk features.
- Your cancer has a specific gene change called an EGFR mutation.
- You have not had any prior cancer treatment for this disease.
- You have had or are planning to have surgery to remove the cancer.
- You are taking or planning to take a third-generation EGFR-TKI pill after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
This trial tests two combination maintenance drugs (a targeted pill and an anti-angiogenesis drug) for people whose non-small cell lung cancer has turned into small cell lung cancer after EGFR-targeted therapy. The goal is to see if this combination can help keep the cancer under control.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
This study tests a combination of two targeted therapies for non-small cell lung cancer that has continued to grow despite previous EGFR-targeted treatment. It aims to see if adding gumarontinib (a MET inhibitor) to another EGFR-targeted drug can control the cancer for longer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.